Claudia Bartolini
Overview
Explore the profile of Claudia Bartolini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mandala M, Bartolini C, Becattini C
Eur J Intern Med
. 2024 Jun;
126:41-42.
PMID: 38852023
No abstract available.
2.
Angeli F, Verdecchia P, Coiro S, Santucci A, Notaristefano F, Bartolini C, et al.
G Ital Cardiol (Rome)
. 2024 Mar;
25(4):262-269.
PMID: 38526362
Superiority trials are designed to test the hypothesis that a given diagnostic or therapeutic strategy is better than (i.e. "superior to") placebo or an active control. Conversely, non-inferiority trials test...
3.
Hurley E, Geisler B, Lupattelli A, Poblador-Plou B, Lassalle R, Jove J, et al.
Eur J Clin Pharmacol
. 2024 Feb;
80(5):707-716.
PMID: 38347228
Purpose: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19,...
4.
Angeli F, Zappa M, Bartolini C, Verdecchia P
G Ital Cardiol (Rome)
. 2023 Nov;
24(12):948-950.
PMID: 38009345
No abstract available.
5.
Convertino I, Cazzato M, Tillati S, Giometto S, Gini R, Valdiserra G, et al.
Front Pharmacol
. 2023 Oct;
14:1244486.
PMID: 37818193
The disease activity associated with the drug-utilization patterns of biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) is poorly investigated in real-world studies on rheumatoid arthritis (RA) patients. To investigate the relationship...
6.
Ferraro S, Cappello E, Bartolini C, Convertino I, Bertani L, Lucenteforte E, et al.
Eur J Gastroenterol Hepatol
. 2023 Sep;
35(11):1263-1269.
PMID: 37724478
Background: A missed diagnosis of Crohn's disease (CD) can delay treatment initiation with consequences on disease course. Aims: To measure the possible impact of missed diagnoses on drug utilization and...
7.
Duran C, Riera-Arnau J, Abtahi S, Pajouheshnia R, Hoxhaj V, Gamba M, et al.
Front Pharmacol
. 2023 Sep;
14:1207976.
PMID: 37663263
In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. To measure the impact...
8.
Bartolini C, Roberto G, Girardi A, Moscatelli V, Spini A, Barchielli A, et al.
Front Oncol
. 2023 Jun;
13:1059109.
PMID: 37324023
Introduction: Italian administrative healthcare databases are frequently used for studies on real-world drug utilization. However, there is currently a lack of evidence on the accuracy of administrative data in describing...
9.
Abtahi S, Pajouheshnia R, Duran C, Riera-Arnau J, Gamba M, Alsina E, et al.
Drug Saf
. 2023 Jun;
46(7):689-702.
PMID: 37294532
Introduction: Due to established teratogenicity of valproates, the EU risk minimisation measures (RMMs) with a pregnancy prevention programme (PPP) for valproate were updated in March 2018. Objectives: To investigate the...
10.
Angeli F, Reboldi G, Solano F, Prosciutto A, Paolini A, Zappa M, et al.
Diagnostics (Basel)
. 2023 May;
13(9).
PMID: 37174992
Several outcome-based prospective investigations have provided solid data which support the prognostic value of 24 h ambulatory blood pressure over and beyond cardiovascular traditional risk factors. Average 24 h, daytime,...